Genexine

Focus: Genexine is a Korean biotechnology company specializing in biologics and DNA plasmid vaccines focused on infectious diseases and cancer immunotherapy. The company operates a diversified pipeline spanning vaccines, immunoncology, and specialty therapeutics.

Infectious Diseases Vaccines

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Genexine

AI assessmentNot Hiring

No open roles listed right now. Follow Genexine to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

GX-I7

Glioblastoma

N/A

Clinical Trials (1)

NCT04289155Individual Patient Compassionate Use of GX-I7

N/A

Help build intelligence for Genexine

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Diverse pipeline with 20+ active clinical programs across vaccines, oncology, and infectious disease—offering broad exposure to multiple therapeutic modalities
Lead position in DNA plasmid vaccine technology, an emerging platform with potential for high-impact vaccine and immunotherapy applications
Geographic advantage as a Seoul-based biotech tapping Asian clinical trial networks and emerging market opportunities

Watch Out For

No marketed products in portfolio limits revenue stability and commercial career progression opportunities
Early-stage pipeline dominated by Phase 1/2 programs (12 Phase 1s vs. only 3 Phase 3s) extends time to potential value inflection
Limited visibility on financial health, funding runway, and hiring freeze (zero active job postings) suggests possible restructuring or capital constraints

Generated by Claude from Genexine's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

GX-188E, GX-I7

Cervical Intraepithelial Neoplasia 3

N/A

Clinical Trials (1)

NCT03206138Safety and Efficacy of GX-188E Administered Via EP Plus GX-I7 or Imiquimod.

N/A

HBsAg vaccine with Entecavir

Chronic Hepatitis B

N/A

Clinical Trials (1)

NCT01813487Study of the Immunogenicity and Efficacy of HBsAg Vaccine in Combination With Standard Antiviral Therapy With HB110E

N/A

GX-188E

Cervical Intraepithelial Neoplasia 3

N/A

Clinical Trials (1)

NCT02411019Safety and Efficacy of GX-188E DNA Therapeutic Vaccine Administered by Electroporation After Observation

N/A

GX-188E

Cervical Intraepithelial Neoplasia 3

N/A

Clinical Trials (1)

NCT02100085Safety and Efficacy of GX-188E DNA Therapeutic Vaccine Administered by Electroporation After Observation

N/A

HB-110

Hepatitis B, Chronic

Phase 1

Clinical Trials (1)

NCT01641536Tolerability, Immunogenicity and Efficacy of HB-110 Administered by Electroporation in Chronic Hepatitis B Patients

Phase 1

GX-051

Head and Neck Cancer

Phase 1

Clinical Trials (1)

NCT02079324Genetically Modified Mesenchymal Stem Cell Theraopeutic Against Head and Neck Cancer

Phase 1

GX-E2

Healthy

Phase 1

Clinical Trials (1)

NCT02291991Study to Evaluate Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GX-E2 in Healthy Subjects

Phase 1

GX-188E administered by electroporation

Cervical Intraepithelial Neoplasia 3

Phase 1

Clinical Trials (1)

NCT01634503Safety of GX-188E DNA Therapeutic Vaccine Administered by Electroporation to Cervical Intraepithelial Neoplasia Grade 3

Phase 1

Gx-G6

Diabetes Mellitus

Phase 1

Clinical Trials (1)

NCT03651466Safety and Tolerability of GX-G6 in Healthy Male Subjects

Phase 1

GX-I7

Solid Tumor

Phase 1

Clinical Trials (1)

NCT03733587GX-I7 With Cyclophosphamide in Patients With Metastatic or Recurrent Solid Tumors

Phase 1

Efepoetin Alfa

Healthy

Phase 1

Clinical Trials (1)

NCT06490939Clinical Trial of Efepoetin Alfa in Healthy Subjects

Phase 1

GX-G3 12.5 μg/kg or Placebo

Healthy

Phase 1

Clinical Trials (1)

NCT01951027Phase I Study GX-G3 in Healthy Subjects

Phase 1

a mixed plasmid DNA

Chronic Hepatitis B

Phase 1

Clinical Trials (1)

NCT00513968Phase I Study to Investigate the Safety and Efficacy of HBV DNA Vaccine

Phase 1

GX-19N

SARS-CoV-2

Phase 1

Clinical Trials (1)

NCT04915989Safety and Immunogenicity of GX-19N, a COVID-19 Preventive DNA Vaccine in Elderly Individuals

Phase 1

GX-P1 or Placebo

Autoimmune Diseases

Phase 1

Clinical Trials (1)

NCT04298749Safety and Tolerability of GX-P1 in Healthy Male Volunteers

Phase 1

GX-12

HIV Infections

Phase 1

Clinical Trials (1)

NCT00517569Gene Therapy With GX-12 in Combination With HAART for the HIV-1 Infected Patients

Phase 1

GX-I7

Healthy

Phase 1

Clinical Trials (1)

NCT02860715Clinical Trial of GX-I7 in Healthy Volunteers

Phase 1

GX-I7

Human Papillomavirus

Phase 1

Clinical Trials (1)

NCT03144934Safety and Tolerability of GX-I7 in HPV-infected Female Volunteers

Phase 1

GX-I7

Locally Advanced or Metastatic Solid Tumors

Phase 1

Clinical Trials (1)

NCT03478995Study to Evaluate Safety and Tolerability of GX-I7 in Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1

GX-I7

Covid19

Phase 1

Clinical Trials (1)

NCT04730427Safety and Preliminary Efficacy Study of GX-I7 in Patients With COVID-19

Phase 1

GX-I7

Newly Diagnosed Glioblastoma

Phase 1

Clinical Trials (1)

NCT03619239Dose-escalation Study to Evaluate the Safety and Tolerability of GX-I7 in Patients With Glioblastoma

Phase 1

Period 1 GX-30, Period 2 THYROGEN®

Total Thyroidectomy

Phase 1/2

Clinical Trials (1)

NCT03276988Tolerability, Safety and Pharmacokinetics Study of GX-30 in Total Thyroidectomy or Near Total Thyroidectomy Patients

Phase 1/2

GX-19N

SARS-CoV-2

Phase 1/2

Clinical Trials (1)

NCT04715997Safety and Immunogenicity Study of GX-19N, a COVID-19 Preventive DNA Vaccine in Healthy Adults

Phase 1/2

GX-188E

Cervical Cancer

Phase 1/2

GX-19

SARS-CoV-2

Phase 1/2

Clinical Trials (1)

NCT04445389Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults

Phase 1/2

GX-I7

Newly Diagnosed Glioblastoma

Phase 1/2

Clinical Trials (1)

NCT04065087Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed Glioblastoma

Phase 1/2

GX-I7

Covid19

Phase 2

Clinical Trials (1)

NCT04810637A Study to Evaluate the Safety and Efficacy of GX-I7 in Elderly Patients With Asymptomatic or Mild Symptoms of COVID-19

Phase 2

GX-G6

Type 2 Diabetes Mellitus

Phase 2

Clinical Trials (1)

NCT03962010A Phase 2, 12-Week, Double-Blind, Efficacy and Safety of GX-G6 in Patients With Uncontrolled Type 2 Diabetes Mellitus

Phase 2

GX-188E, GX-I7, Pembrolizumab

Head and Neck Squamous Cell Carcinoma

Phase 2

Clinical Trials (1)

NCT05286060Trial of the Combination of GX-188E Vaccination, GX-I7 and Pembrolizumab in Patients With Advanced, Resectable HPV Type 16 and/or 18 Positive Head and Neck Cancer

Phase 2

GX-E2

Anemia

Phase 2

Clinical Trials (1)

NCT02044653Study to Evaluate the Efficacy and Safety of GX-E2 in the Anemic Patients Diagnosed With Chronic Kidney Disease (CKD)

Phase 2

GX-H9

Adult Growth Hormone Deficiency

Phase 2

Clinical Trials (1)

NCT02946606A Clinical Study in AGHD to Assess Safety, Tolerability and Efficacy of GX-H9